External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers-Reference-Cited by-同舟云学术

External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers

Published:2020-01-06 Issue:10 Volume:38 Page:2555-2561
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Cindolo Luca,Bertolo Riccardo^ORCID,Minervini Andrea,Sessa Francesco,Muto Gianluca,Bove Pierluigi,Vittori Matteo,Bozzini Giorgio,Castellan Pietro,Mugavero Filippo,Falsaperla Mario,Schips Luigi,Celia Antonio,Bada Maida,Porreca Angelo,Pastore Antonio,Al Salhi Yazan,Giampaoli Marco,Novella Giovanni,Rizzetto Riccardo,Trabacchin Nicoló,Mantica Guglielmo,Pini Giovannalberto,Lombardo Riccardo,Tubaro Andrea,Antonelli Alessandro,De Nunzio Cosimo

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-019-03058-1.pdf

Reference29 articles.

1. EAU guidelines: prostate cancer (2019). https://uroweb.org/guideline/prostate-cancer/#5. Accessed 17 Aug 2019

2. Serag H, Banerjee S, Saeb-Parsy K, Irving S, Wright K, Stearn S et al (2012) Risk profiles of prostate cancers identified from UK primary care using national referral guidelines. Br J Cancer 106:436–439. https://doi.org/10.1038/bjc.2011.596

3. Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ (2012) Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial. BJU Int 110:1654–1660. https://doi.org/10.1111/j.1464-410X.2012.11481.x

4. Louie KS, Seigneurin A, Cathcart P, Sasieni P (2015) Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 26:848–864. https://doi.org/10.1093/annonc/mdu525

5. Vedder MM, Bekker-Grob EW, Lilja HG, Vickers AJ, Leenders GJ, Steyerberg EW, Roobol MJ (2014) The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 66(6):1109–1115

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care Center;Diagnostics;2024-06-05

2. Based on PI‐RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4−20 ng/mL;The Prostate;2023-12-20

3. Foggia Prostate Cancer Risk Calculator 2.0: A Novel Risk Calculator including MRI and Bladder Outlet Obstruction Parameters to Reduce Unnecessary Biopsies;International Journal of Molecular Sciences;2023-01-26

4. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer;International Urology and Nephrology;2021-10-22

5. Development of a nomogram predicting the probability of stone free rate in patients with ureteral stones eligible for semi-rigid primary laser uretero-litothripsy;World Journal of Urology;2021-06-26